Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.6.3.1 (
NADPH oxidase
)
11,281
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We previously found that the angiogenic factors TNFalpha and HIV-1 Tat activate an
NAD(P)H oxidase
in endothelial cells, which operates upstream of c-Jun N-terminal kinase (JNK), a MAPK involved in the determination of cell fate. To further understand oxidant-related signaling pathways, we screened lung and endothelial cell libraries for interaction partners of p47(phox) and recovered the orphan adapter
TNF receptor-associated factor 4
(
TRAF4
). Domain analysis suggested a tail-to-tail interaction between the C terminus of p47(phox) and the conserved TRAF domain of
TRAF4
. In addition,
TRAF4
, like p47(phox), was recovered largely in the cytoskeleton/membrane fraction. Coexpression of p47(phox) and
TRAF4
increased oxidant production and JNK activation, whereas each alone had minimal effect. In addition, a fusion between p47(phox) and the
TRAF4
C terminus constitutively activated JNK, and this activation was decreased by the antioxidant N-acetyl cysteine. In contrast, overexpression of the p47(phox) binding domain of
TRAF4
blocked endothelial cell JNK activation by TNFalpha and HIV-1 Tat, suggesting an uncoupling of p47(phox) from upstream signaling events. A secondary screen of endothelial cell proteins for
TRAF4
-interacting partners yielded a number of proteins known to control cell fate. We conclude that endothelial cell agonists such as TNFalpha and HIV-1 Tat initiate signals that enter basic signaling cassettes at the level of
TRAF4
and an
NAD(P)H oxidase
. We speculate that endothelial cells may target endogenous oxidant production to specific sites critical to cytokine signaling as a mechanism for increasing signal specificity and decreasing toxicity of these reactive species.
...
PMID:Involvement of TRAF4 in oxidative activation of c-Jun N-terminal kinase. 1202 63